PDLI Related Guidance
-
PDL BioPharma (PDLI) Updates on Royalty Revs for Q4
-
PDL BioPharma (PDLI) Sees Q2 Revs Ahead of Views
-
PDL BioPharma (PDLI) Guides Q4, FY11 Revs Below Views
-
PDL BioPharma (PDLI) Release Q3 Revenue Guidance Well Below Consensus
-
PDL BioPharma (PDLI) Releases Q2 Revenue Guidance at $128 Million
-
PDL BioPharma (PDLI) Sees Q111 Revs Ahead of Street
-
PDL BioPharma (PDLI) Guides Q4 Revenue In Line With Street
-
PDL BioPharma (PDLI) Updates Q310 Outlook; Sees Revs Above Street Consensus
-
PDL BioPharma (PDLI) Issues Q2 Guidance; Sees Q2 Revs Lower Y/Y
-
PDL BioPharma (PDLI) Posts Q4 EPS of $0.17, Tops by 2c; Guides Q110 Sales Below Street
-
PDL BioPharma (PDLI) Reports Q4 Revenues
-
PDL BioPharma (PDLI) Reports Mixed Q3 Results; Narrows FY09 Sales Guidance
-
PDL BioPharma (PDLI) Guides Q3 Revenues Below Street Views
-
PDL BioPharma (PDLI) Sees Q2 Revenues of $125M
-
PDL BioPharma (PDLI) Reports Mixed Q1 Results; Re-affirms
-
PDL BioPharma (PDLI) Issues Q1 Sales Outlook
-
PDL BioPharma (PDLI) Reports Q3 EPS of $0.16; Suspends Guidance for FY07
-
PDL BioPharma (PDLI) Misses Q1 EPS by 3c; Guides
-
PDL BioPharma (PDLI) Reports Q3 Results; Guide
-
PDL BioPharma (PDLI) Misses Q1 EPS by 12c, Guides For Full-Year
-
PDLI Tops Q4 EPS; Guides
-
PDLI Reported a Q3 Loss; Guides
-
PDLI Reported a Q4 Loss
Back to PDLI Stock Lookup
